2026-05-28T12:23:17Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/410732026-02-03T11:16:23Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Sánchez-Muñoz, Alfonso author Alba-Conejo, Emilio author Godoy-Ortiz, Ana author Lendínez-Sanchez, Gonzalo author Pascual, Javier author Zalabardo, Manuel author Cantero, Alexandra author Carabantes, Francisco author Pajares, Bella author Rueda Dominguez, Antonio author Domínguez Recio, María Emilia author Iglesias, Marcos author Villar, Ester author Bermejo, María José author Ribelles, Nuria author Diaz Redondo, Tamara author 2025-11-16 Purpose: Evaluate real-world outcomes in three cohorts of patients with early-stage triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC): (1) patients who achieved pathological complete response (pCR); (2) patients without pCR who didn’t receive adjuvant chemotherapy; and (3) patients without pCR who received adjuvant capecitabine. Methods: Retrospective cross-sectional study from two hospitals in Málaga. Patients with TNBC received standard NAC followed by surgery. Between 2004 and 2015, patients not achieving pCR received no further systemic therapy. From 2015 onward, these patients were treated with adjuvant capecitabine. Kaplan–Meier and log-rank tests were used to compare disease-free survival (DFS) and overall survival (OS). Results: A total of 312 patients were included in the study. 133 achieved pCR, 84 patients didn’t achieve pCR and didn’t receive adjuvant capecitabine and 95 patients didn’t reach pCR and received adjuvant capecitabine. 89 patients experienced recurrence and 70 patients died. Patients who achieved pCR had a significantly higher DFS (HR 0.21 CI95% 0.12-0.36, p<0.0001) and higher overall survival (HR 0.27 CI95% 0.15-0.49, p<0.0001) compared to those who didn’t. Statistically significant differences in DFS and OS were observed among the three cohorts (DFS: p<0.00001; OS: p=0.00005). However, no statistically significant differences were found between cohorts 2 and 3 in terms of DFS (p=0.94) or OS (p=0.34). Conclusions: Patients who achieved pCR had better outcomes compared to those who didn’t. Among patients who didn’t achieve pCR, the addition of capecitabine didn’t result in significant improvements in DFS or OS compared to those who didn’t receive adjuvant treatment. Godoy-Ortíz A, Lendínez-Sánchez G, Zalabardo M, Pascual J, López-Pascual A, Cantero A, Ribelles N, Iglesias M, Villar E, Pajares B, Díaz-Redondo T, Domínguez-Recio ME, Carabantes F, Bermejo MJ, Rueda-Domínguez A, Alba E, Sánchez-Muñoz A. Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy. Front Oncol. 2025 Nov 17;15:1648272. doi: 10.3389/fonc.2025.1648272. PMID: 41333222; PMCID: PMC12665565. https://hdl.handle.net/10630/41073 doi.org/10.3389/fonc.2025.1648272 Mamas - Cáncer Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy